"Mad Money" host Jim Cramer reveals a stock that could gallop higher.» Read More
From Kimberly-Clark to Core Labs, CEOs tell “Mad Money” host Jim Cramer what can power their companies higher.
“Mad Money” host Jim Cramer reveals a stock that could gallop higher.
Don't get shaken by the SHAK! Jim Cramer warns investors on what to expect with Shake Shack.
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Despite the confusion with Google, Jim Cramer thinks there is a method to its spending madness.
Jim Cramer is gearing up for earnings next week, especially the oil companies.
CNBC's Melissa Lee and the Options Action traders discuss the stocks they'll be watching next week.
What's in store for the biggest CAT of them all? Could the stock fall to its lowest level since 2011? With CNBC's Melissa Lee and the Options Action traders. Also, the Qualcomm & Alibaba trades.
Is the VIX signaling a buy sign? Why it could be time to buy, with CNBC's Melissa Lee and the Options Action traders.
The Green Mountain earnings call. Should investors dump high flyers into earnings? With CNBC's Melissa Lee and the Options Action traders.
Disney is among the Dow's top stocks so far this year. Is it time to bet against the Magic Kingdom? With CNBC's Melissa Lee and the Options Action traders.
The Fast Money traders share their final trades of the day.
The Fast Money traders take a look at today's biggest market movers.
Ritu Baral, Cowen and Company, finds opportunity in the biotech space.
The "Fast Money" traders give 3 reasons to be bearish on Shake Shack.
Data showed the number of rigs fell by 94 this week. How it impacted markets, with the Fast Money traders.
How to position yourself on Shake Shack following its IPO, with the FM traders.
Joe Terranova, "Halftime Report" trader and chief market strategist at Virtus Investment Partners, is adding another energy company to his portfolio.
John Schroer, Allianz portfolio manager, shares his thoughts on precision medicine, and reveals his top biotech stock picks.
You don't need to love Yahoo, just math to justify buying the stock, according to one analyst.